Fri, 23 Jan 2004 16:45:00 Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect ...

Indeed, DEFENSE-PFO was originally designed to be a 210-patient trial, with subjects randomized equally to PFO closure or medical therapy at the treating physician’s discretion. Following the release ...

Atrial septal defect (ASD) is a congenital disease. This means that children and babies who have ASD have it as soon as they’re born. ASD doesn’t develop later in life. If you have a hole in the wall ...

A single-center report of 100 cases of percutaneous device closure of patent foramen ovale and atrial-septal defects shows excellent results in terms of defect closure, with few complications. The ...

Percutaneous closure can be described as a less-invasive surgical procedure that is used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of ...

Prof. Dr. Horst Sievert of the Cardiovascular Center, Frankfurt, successfully completed five PFO closures using the NobleStitch™ EL-marking the official sales release of the NobleStitch ...

Dr. Niels Erik Nielsen, Director of Structural Heart Interventions at the Linkoping University Hospital in Linkoping Sweden, successfully performed the first ever percutaneous ASD closure and ASA ...

FLAGSTAFF, Ariz., April 3, 2018 /PRNewswire/ -- Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes ...

DUBAI, United Arab Emirates, May 2, 2017 /PRNewswire/ -- Nobles Medical Technologies™ II (NMT2) continues to expand its clinical experience in septal repair to include ASD closure. Prof. Anthony ...

The market for these devices, and the PFO occluders in particular, areexpected to expand significantly over the next few years.For further information please contact: Robert Moszner e-mail: [email ...

The researchers found that 108 individuals were diagnosed with epilepsy at an average follow-up of 2.19 years. Epilepsy incidence in patients with PFO, VSD, PDA, and ASD was 8.58, 4.85, 3.98, and ...